<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34861941</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0423-2607</ISSN><JournalIssue CitedMedium="Print"><Volume>50</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>The Enzymes</Title><ISOAbbreviation>Enzymes</ISOAbbreviation></Journal><ArticleTitle>Viral proteases: Structure, mechanism and inhibition.</ArticleTitle><Pagination><StartPage>301</StartPage><EndPage>333</EndPage><MedlinePgn>301-333</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/bs.enz.2021.09.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1874-6047(21)00021-4</ELocationID><Abstract><AbstractText>Viral proteases are diverse in structure, oligomeric state, catalytic mechanism, and substrate specificity. This chapter focuses on proteases from viruses that are relevant to human health: human immunodeficiency virus subtype 1 (HIV-1), hepatitis C (HCV), human T-cell leukemia virus type 1 (HTLV-1), flaviviruses, enteroviruses, and coronaviruses. The proteases of HIV-1 and HCV have been successfully targeted for therapeutics, with picomolar FDA-approved drugs currently used in the clinic. The proteases of HTLV-1 and the other virus families remain emerging therapeutic targets at different stages of the drug development process. This chapter provides an overview of the current knowledge on viral protease structure, mechanism, substrate recognition, and inhibition. Particular focus is placed on recent advances in understanding the molecular basis of diverse substrate recognition and resistance, which is essential toward designing novel protease inhibitors as antivirals.</AbstractText><CopyrightInformation>Copyright © 2021 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zephyr</LastName><ForeName>Jacqueto</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurt Yilmaz</LastName><ForeName>Nese</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiffer</LastName><ForeName>Celia A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA, United States. Electronic address: celia.schiffer@umassmed.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F31 GM131635</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI085051</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM135919</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI149716</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Enzymes</MedlineTA><NlmUniqueID>101637215</NlmUniqueID><ISSNLinking>1874-6047</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D000085242">Viral Proteases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006526" MajorTopicYN="Y">Hepatitis C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000085242" MajorTopicYN="Y">Viral Proteases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">Drug resistance</Keyword><Keyword MajorTopicYN="N">Enterovirus</Keyword><Keyword MajorTopicYN="N">Flavivirus</Keyword><Keyword MajorTopicYN="N">HCV</Keyword><Keyword MajorTopicYN="N">HIV-1</Keyword><Keyword MajorTopicYN="N">HTLV-1</Keyword><Keyword MajorTopicYN="N">Protease inhibitors</Keyword><Keyword MajorTopicYN="N">Substrate envelope</Keyword><Keyword MajorTopicYN="N">Viral protease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>4</Day><Hour>5</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34861941</ArticleId><ArticleId IdType="pmc">PMC8595904</ArticleId><ArticleId IdType="doi">10.1016/bs.enz.2021.09.004</ArticleId><ArticleId IdType="pii">S1874-6047(21)00021-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ghosh A.K., Osswald H.L., Prato G. Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV/AIDS. J. Med. Chem. 2016;59(11):5172–5208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5598487</ArticleId><ArticleId IdType="pubmed">26799988</ArticleId></ArticleIdList></Reference><Reference><Citation>Brik A., Wong C.H. HIV-1 protease: mechanism and drug discovery. Org. Biomol. Chem. 2003;1(1):5–14.</Citation><ArticleIdList><ArticleId IdType="pubmed">12929379</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson J., Schiffer C., Lee S.K., Swanstrom R. Viral protease inhibitors. Handb. Exp. Pharmacol. 2009;189:85–110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7120715</ArticleId><ArticleId IdType="pubmed">19048198</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabu-Jeyabalan M., Nalivaika E., Schiffer C.A. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure. 2002;10(3):369–381.</Citation><ArticleIdList><ArticleId IdType="pubmed">12005435</ArticleId></ArticleIdList></Reference><Reference><Citation>Chellappan S., Kairys V., Fernandes M.X., Schiffer C., Gilson M.K. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease. Proteins. 2007;68(2):561–567.</Citation><ArticleIdList><ArticleId IdType="pubmed">17474129</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozen A., Haliloglu T., Schiffer C.A. Dynamics of preferential substrate recognition in HIV-1 protease: redefining the substrate envelope. J. Mol. Biol. 2011;410(4):726–744.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3139114</ArticleId><ArticleId IdType="pubmed">21762811</ArticleId></ArticleIdList></Reference><Reference><Citation>Leidner F., Kurt Yilmaz N., Schiffer C.A. Deciphering complex mechanisms of resistance and loss of potency through coupled molecular dynamics and machine learning. J. Chem. Theory Comput. 2021;17(4):2054–2064.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8164521</ArticleId><ArticleId IdType="pubmed">33783217</ArticleId></ArticleIdList></Reference><Reference><Citation>Özen A., Schiffer C.A. Structural Biology in Drug Discovery. 2020. Integrating evolution of drug resistance into drug discovery; pp. 521–543.</Citation></Reference><Reference><Citation>Henes M., Kosovrasti K., Lockbaum G.J., Leidner F., Nachum G.S., Nalivaika E.A., Bolon D.N.A., Kurt Yilmaz N., Schiffer C.A., Whitfield T.W. Molecular determinants of epistasis in HIV-1 protease: elucidating the interdependence of L89V and L90M mutations in resistance. Biochemistry. 2019;58(35):3711–3726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6941756</ArticleId><ArticleId IdType="pubmed">31386353</ArticleId></ArticleIdList></Reference><Reference><Citation>Henes M., Lockbaum G.J., Kosovrasti K., Leidner F., Nachum G.S., Nalivaika E.A., Lee S.K., Spielvogel E., Zhou S., Swanstrom R., Bolon D.N.A., Kurt Yilmaz N., Schiffer C.A. Picomolar to micromolar: elucidating the role of distal mutations in HIV-1 protease in conferring drug resistance. ACS Chem. Biol. 2019;14(11):2441–2452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6941144</ArticleId><ArticleId IdType="pubmed">31361460</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishima R., Kurt Yilmaz N., Schiffer C.A. NMR and MD studies combined to elucidate inhibitor and water interactions of HIV-1 protease and their modulations with resistance mutations. J. Biomol. NMR. 2019;73(6–7):365–374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6941145</ArticleId><ArticleId IdType="pubmed">31243634</ArticleId></ArticleIdList></Reference><Reference><Citation>Leidner F., Kurt Yilmaz N., Paulsen J., Muller Y.A., Schiffer C.A. Hydration structure and dynamics of inhibitor-bound HIV-1 protease. J. Chem. Theory Comput. 2018;14(5):2784–2796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6219750</ArticleId><ArticleId IdType="pubmed">29570286</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragland D.A., Nalivaika E.A., Nalam M.N., Prachanronarong K.L., Cao H., Bandaranayake R.M., Cai Y., Kurt-Yilmaz N., Schiffer C.A. Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease. J. Am. Chem. Soc. 2014;136(34):11956–11963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4151706</ArticleId><ArticleId IdType="pubmed">25091085</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y., Myint W., Paulsen J.L., Schiffer C.A., Ishima R., Kurt Yilmaz N. Drug resistance mutations Alter dynamics of inhibitor-bound HIV-1 protease. J Chem Theory Comput. 2014;10(8):3438–3448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4132871</ArticleId><ArticleId IdType="pubmed">25136270</ArticleId></ArticleIdList></Reference><Reference><Citation>Foulkes-Murzycki J.E., Rosi C., Kurt Yilmaz N., Shafer R.W., Schiffer C.A. Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease. ACS Chem. Biol. 2013;8(3):513–518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3805267</ArticleId><ArticleId IdType="pubmed">23252515</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y., Yilmaz N.K., Myint W., Ishima R., Schiffer C.A. Differential flap dynamics in wild-type and a drug resistant variant of HIV-1 protease revealed by molecular dynamics and NMR relaxation. J. Chem. Theory Comput. 2012;8(10):3452–3462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3491577</ArticleId><ArticleId IdType="pubmed">23144597</ArticleId></ArticleIdList></Reference><Reference><Citation>King N.M., Prabu-Jeyabalan M., Bandaranayake R.M., Nalam M.N., Nalivaika E.A., Ozen A., Haliloglu T., Yilmaz N.K., Schiffer C.A. Extreme entropy-enthalpy compensation in a drug-resistant variant of HIV-1 protease. ACS Chem. Biol. 2012;7(9):1536–1546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3594831</ArticleId><ArticleId IdType="pubmed">22712830</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y., Schiffer C. In: Computational Drug Discovery and Design. Baron R., editor. Springer New York; New York, NY: 2012. Decomposing the energetic impact of drug-resistant mutations: the example of HIV-1 protease–DRV binding; pp. 551–560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4868624</ArticleId><ArticleId IdType="pubmed">22183557</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali A., Bandaranayake R.M., Cai Y., King N.M., Kolli M., Mittal S., Murzycki J.F., Nalam M.N., Nalivaika E.A., Ozen A., Prabu-Jeyabalan M.M., Thayer K., Schiffer C.A. Molecular basis for drug resistance in HIV-1 protease. Viruses. 2010;2(11):2509–2535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3185577</ArticleId><ArticleId IdType="pubmed">21994628</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragland D.A., Whitfield T.W., Lee S.K., Swanstrom R., Zeldovich K.B., Kurt-Yilmaz N., Schiffer C.A. Elucidating the interdependence of drug resistance from combinations of mutations. J. Chem. Theory Comput. 2017;13(11):5671–5682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5927819</ArticleId><ArticleId IdType="pubmed">28915040</ArticleId></ArticleIdList></Reference><Reference><Citation>King N.M., Prabu-Jeyabalan M., Nalivaika E.A., Schiffer C.A. Combating susceptibility to drug resistance: lessons from HIV-1 protease. Chem. Biol. 2004;11(10):1333–1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">15489160</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthew A.N., Leidner F., Lockbaum G.J., Henes M., Zephyr J., Hou S., Rao D.N., Timm J., Rusere L.N., Ragland D.A., Paulsen J.L., Prachanronarong K., Soumana D.I., Nalivaika E.A., Kurt Yilmaz N., Ali A., Schiffer C.A. Drug design strategies to avoid resistance in direct-acting antivirals and beyond. Chem. Rev. 2021;121(6):3238–3270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8126998</ArticleId><ArticleId IdType="pubmed">33410674</ArticleId></ArticleIdList></Reference><Reference><Citation>Yilmaz N.K., Schiffer C.A. In: Antimicrobial Drug Resistance: Mechanisms of Drug Resistance, Volume 1. Mayers D.L., et al., editors. Springer International Publishing; Cham: 2017. Drug resistance to HIV-1 protease inhibitors: molecular mechanisms and substrate coevolution; pp. 535–544.</Citation></Reference><Reference><Citation>Kurt Yilmaz N., Swanstrom R., Schiffer C.A. Improving viral protease inhibitors to counter drug resistance. Trends Microbiol. 2016;24(7):547–557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4912444</ArticleId><ArticleId IdType="pubmed">27090931</ArticleId></ArticleIdList></Reference><Reference><Citation>Özen A., Schiffer C.A. In: Handbook of Antimicrobial Resistance. Berghuis A., et al., editors. 149-173. Springer New York; New York, NY: 2017. Substrate-envelope-guided design of drugs with a high barrier to the evolution of resistance.</Citation></Reference><Reference><Citation>Nalam M.N., Ali A., Altman M.D., Reddy G.S., Chellappan S., Kairys V., Ozen A., Cao H., Gilson M.K., Tidor B., Rana T.M., Schiffer C.A. Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance. J. Virol. 2010;84(10):5368–5378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2863851</ArticleId><ArticleId IdType="pubmed">20237088</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusere L.N., Lockbaum G.J., Henes M., Lee S.K., Spielvogel E., Rao D.N., Kosovrasti K., Nalivaika E.A., Swanstrom R., Kurt Yilmaz N., Schiffer C.A., Ali A. Structural analysis of potent hybrid HIV-1 protease inhibitors containing Bis-tetrahydrofuran in a Pseudosymmetric dipeptide Isostere. J. Med. Chem. 2020;63(15):8296–8313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7971191</ArticleId><ArticleId IdType="pubmed">32672965</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusere L.N., Lockbaum G.J., Lee S.K., Henes M., Kosovrasti K., Spielvogel E., Nalivaika E.A., Swanstrom R., Yilmaz N.K., Schiffer C.A., Ali A. HIV-1 protease inhibitors incorporating Stereochemically defined P2' ligands to optimize hydrogen bonding in the substrate envelope. J. Med. Chem. 2019;62(17):8062–8079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6941148</ArticleId><ArticleId IdType="pubmed">31386368</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockbaum G.J., Leidner F., Rusere L.N., Henes M., Kosovrasti K., Nachum G.S., Nalivaika E.A., Ali A., Yilmaz N.K., Schiffer C.A. Structural adaptation of Darunavir analogues against primary mutations in HIV-1 protease. ACS Infect. Dis. 2019;5(2):316–325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6941150</ArticleId><ArticleId IdType="pubmed">30543749</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalam M.N., Ali A., Reddy G.S., Cao H., Anjum S.G., Altman M.D., Yilmaz N.K., Tidor B., Rana T.M., Schiffer C.A. Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance. Chem. Biol. 2013;20(9):1116–1124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3934494</ArticleId><ArticleId IdType="pubmed">24012370</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindenbach B.D., Rice C.M. Molecular biology of flaviviruses. Adv. Virus Res. 2003;59:23–61.</Citation><ArticleIdList><ArticleId IdType="pubmed">14696326</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartenschlager R., Ahlborn-Laake L., Mous J., Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J. Virol. 1993;67(7):3835–3844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC237748</ArticleId><ArticleId IdType="pubmed">8389908</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckart M.R., Selby M., Masiarz F., Lee C., Berger K., Crawford K., Kuo C., Kuo G., Houghton M., Choo Q.L. The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor. Biochem. Biophys. Res. Commun. 1993;192(2):399–406.</Citation><ArticleIdList><ArticleId IdType="pubmed">8387277</ArticleId></ArticleIdList></Reference><Reference><Citation>Grakoui A., McCourt D.W., Wychowski C., Feinstone S.M., Rice C.M. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J. Virol. 1993;67(5):2832–2843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC237608</ArticleId><ArticleId IdType="pubmed">8386278</ArticleId></ArticleIdList></Reference><Reference><Citation>Grakoui A., Wychowski C., Lin C., Feinstone S.M., Rice C.M. Expression and identification of hepatitis C virus polyprotein cleavage products. J. Virol. 1993;67(3):1385–1395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC237508</ArticleId><ArticleId IdType="pubmed">7679746</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijikata M., Mizushima H., Akagi T., Mori S., Kakiuchi N., Kato N., Tanaka T., Kimura K., Shimotohno K. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J. Virol. 1993;67(8):4665–4675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC237852</ArticleId><ArticleId IdType="pubmed">8392606</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijikata M., Mizushima H., Tanji Y., Komoda Y., Hirowatari Y., Akagi T., Kato N., Kimura K., Shimotohno K. Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 1993;90(22):10773–10777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47860</ArticleId><ArticleId IdType="pubmed">7504283</ArticleId></ArticleIdList></Reference><Reference><Citation>Grakoui A., McCourt D.W., Wychowski C., Feinstone S.M., Rice C.M. A second hepatitis C virus-encoded proteinase. Proc. Natl. Acad. Sci. U. S. A. 1993;90(22):10583–10587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47821</ArticleId><ArticleId IdType="pubmed">8248148</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano K.P., Ali A., Royer W.E., Schiffer C.A. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc. Natl. Acad. Sci. U. S. A. 2010;107(49):20986–20991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000259</ArticleId><ArticleId IdType="pubmed">21084633</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozen A., Sherman W., Schiffer C.A. Improving the resistance profile of hepatitis C NS3/4A inhibitors: dynamic substrate envelope guided design. J. Chem. Theory Comput. 2013;9(12):5693–5705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3935243</ArticleId><ArticleId IdType="pubmed">24587770</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedstrom L. Serine protease mechanism and specificity. Chem. Rev. 2002;102(12):4501–4524.</Citation><ArticleIdList><ArticleId IdType="pubmed">12475199</ArticleId></ArticleIdList></Reference><Reference><Citation>Copeland R.A. Wiley–VCH (Wiley–India); New Delhi, India: 2008. Enzymes : a Practical introduction to structure, mechanism, and data analysis.</Citation></Reference><Reference><Citation>Soumana D.I., Kurt Yilmaz N., Prachanronarong K.L., Aydin C., Ali A., Schiffer C.A. Structural and thermodynamic effects of macrocyclization in HCV NS3/4A inhibitor MK-5172. ACS Chem. Biol. 2016;11(4):900–909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5099976</ArticleId><ArticleId IdType="pubmed">26682473</ArticleId></ArticleIdList></Reference><Reference><Citation>Timm J., Kosovrasti K., Henes M., Leidner F., Hou S., Ali A., Kurt Yilmaz N., Schiffer C.A. Molecular and structural mechanism of Pan-genotypic HCV NS3/4A protease inhibition by Glecaprevir. ACS Chem. Biol. 2020;15(2):342–352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7747061</ArticleId><ArticleId IdType="pubmed">31868341</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozen A., Prachanronarong K., Matthew A.N., Soumana D.I., Schiffer C.A. Resistance outside the substrate envelope: hepatitis C NS3/4A protease inhibitors. Crit. Rev. Biochem. Mol. Biol. 2019;54(1):11–26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7717897</ArticleId><ArticleId IdType="pubmed">30821513</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X. Direct anti-HCV agents. Acta Pharm. Sin B. 2016;6(1):26–31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4724659</ArticleId><ArticleId IdType="pubmed">26904396</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthew A.N., Zephyr J., Hill C.J., Jahangir M., Newton A., Petropoulos C.J., Huang W., Kurt-Yilmaz N., Schiffer C.A., Ali A. Hepatitis C virus NS3/4A protease inhibitors incorporating flexible P2 Quinoxalines target drug resistant viral variants. J. Med. Chem. 2017;60(13):5699–5716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5748155</ArticleId><ArticleId IdType="pubmed">28594175</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthew A.N., Zephyr J., Nageswara Rao D., Henes M., Kamran W., Kosovrasti K., Hedger A.K., Lockbaum G.J., Timm J., Ali A., Kurt Yilmaz N., Schiffer C.A. Avoiding drug resistance by substrate envelope-guided design: toward potent and robust HCV NS3/4A protease inhibitors. mBio. 2020;11(2):e00172–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7157764</ArticleId><ArticleId IdType="pubmed">32234812</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano K.P., Ali A., Aydin C., Soumana D., Ozen A., Deveau L.M., Silver C., Cao H., Newton A., Petropoulos C.J., Huang W., Schiffer C.A. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog. 2012;8(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3406087</ArticleId><ArticleId IdType="pubmed">22910833</ArticleId></ArticleIdList></Reference><Reference><Citation>Soumana D.I., Ali A., Schiffer C.A. Structural analysis of asunaprevir resistance in HCV NS3/4A protease. ACS Chem. Biol. 2014;9(11):2485–2490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4245159</ArticleId><ArticleId IdType="pubmed">25243902</ArticleId></ArticleIdList></Reference><Reference><Citation>Soumana D.I., Kurt Yilmaz N., Ali A., Prachanronarong K.L., Schiffer C.A. Molecular and dynamic mechanism underlying drug resistance in genotype 3 hepatitis C NS3/4A protease. J. Am. Chem. Soc. 2016;138(36):11850–11859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5221612</ArticleId><ArticleId IdType="pubmed">27512818</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali A., Aydin C., Gildemeister R., Romano K.P., Cao H., Ozen A., Soumana D., Newton A., Petropoulos C.J., Huang W., Schiffer C.A. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. ACS Chem. Biol. 2013;8(7):1469–1478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3884027</ArticleId><ArticleId IdType="pubmed">23594083</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonsall D., Black S., Howe A.Y., Chase R., Ingravallo P., Pak I., Brown A., Smith D.A., Bowden R., Barnes E. Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse. Infect Drug Resist. 2018;11:1119–1135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6089106</ArticleId><ArticleId IdType="pubmed">30127629</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeuzem S., Foster G.R., Wang S., Asatryan A., Gane E., Feld J.J., Asselah T., Bourliere M., Ruane P.J., Wedemeyer H., Pol S., Flisiak R., Poordad F., Chuang W.L., Stedman C.A., Flamm S., Kwo P., Dore G.J., Sepulveda-Arzola G., Roberts S.K., Soto-Malave R., Kaita K., Puoti M., Vierling J., Tam E., Vargas H.E., Bruck R., Fuster F., Paik S.W., Felizarta F., Kort J., Fu B., Liu R., Ng T.I., Pilot-Matias T., Lin C.W., Trinh R., Mensa F.J. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378(4):354–369.</Citation><ArticleIdList><ArticleId IdType="pubmed">29365309</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthew A.N., Leidner F., Newton A., Petropoulos C.J., Huang W., Ali A., KurtYilmaz N., Schiffer C.A. Molecular mechanism of resistance in a clinically significant double-mutant variant of HCV NS3/4A protease. Structure. 2018;26(10):1360–1372. (e5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6260965</ArticleId><ArticleId IdType="pubmed">30146168</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusere L.N., Matthew A.N., Lockbaum G.J., Jahangir M., Newton A., Petropoulos C.J., Huang W., Kurt Yilmaz N., Schiffer C.A., Ali A. Quinoxaline-based linear HCV NS3/4A protease inhibitors exhibit potent activity against drug resistant variants. ACS Med. Chem. Lett. 2018;9(7):691–696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6047049</ArticleId><ArticleId IdType="pubmed">30034602</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewan M.Z., Uchihara J.N., Terashima K., Honda M., Sata T., Ito M., Fujii N., Uozumi K., Tsukasaki K., Tomonaga M., Kubuki Y., Okayama A., Toi M., Mori N., Yamamoto N. Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir. Blood. 2006;107(2):716–724.</Citation><ArticleIdList><ArticleId IdType="pubmed">16174765</ArticleId></ArticleIdList></Reference><Reference><Citation>Tozser J., Weber I.T. The protease of human T-cell leukemia virus type-1 is a potential therapeutic target. Curr. Pharm. Des. 2007;13(12):1285–1294.</Citation><ArticleIdList><ArticleId IdType="pubmed">17504236</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuker S.B., Mariani V.L., Herger B.E., Dennison K.J. Understanding HTLV-I protease. Chem. Biol. 2003;10(5):373–380.</Citation><ArticleIdList><ArticleId IdType="pubmed">12770819</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata D., Brynes R.K., Rabinowitz A., Hanson C.A., Slovak M.L., Spira T.J., Gill P. Human T-cell lymphotropic virus type I (HTLV-I)-associated adult T-cell leukemia-lymphoma in a patient infected with human immunodeficiency virus type 1 (HIV-1) Ann. Intern. Med. 1989;111(11):871–875.</Citation><ArticleIdList><ArticleId IdType="pubmed">2573306</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M., Laco G.S., Jaskolski M., Rozycki J., Alexandratos J., Wlodawer A., Gustchina A. Crystal structure of human T cell leukemia virus protease, a novel target for anticancer drug design. Proc. Natl. Acad. Sci. U. S. A. 2005;102(51):18332–18337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1317974</ArticleId><ArticleId IdType="pubmed">16352712</ArticleId></ArticleIdList></Reference><Reference><Citation>Wattel E., Vartanian J.P., Pannetier C., Wain-Hobson S. Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. J. Virol. 1995;69(5):2863–2868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC188982</ArticleId><ArticleId IdType="pubmed">7707509</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh T., Li M., Nguyen J.T., Kiso Y., Gustchina A., Wlodawer A. Crystal structures of inhibitor complexes of human T-cell leukemia virus (HTLV-1) protease. J. Mol. Biol. 2010;401(4):626–641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2918672</ArticleId><ArticleId IdType="pubmed">20600105</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M., Nguyen J.T., Kumada H.O., Kimura T., Cheng M., Hayashi Y., Kiso Y. Locking the two ends of tetrapeptidic HTLV-I protease inhibitors inside the enzyme. Bioorg. Med. Chem. 2008;16(14):6880–6890.</Citation><ArticleIdList><ArticleId IdType="pubmed">18558491</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagossi P., Kadas J., Miklossy G., Boross P., Weber I.T., Tozser J. Development of a microtiter plate fluorescent assay for inhibition studies on the HTLV-1 and HIV-1 proteinases. J. Virol. Methods. 2004;119(2):87–93.</Citation><ArticleIdList><ArticleId IdType="pubmed">15158589</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhnert M., Steuber H., Diederich W.E. Structural basis for HTLV-1 protease inhibition by the HIV-1 protease inhibitor indinavir. J. Med. Chem. 2014;57(14):6266–6272.</Citation><ArticleIdList><ArticleId IdType="pubmed">25006983</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockbaum G.J., Henes M., Talledge N., Rusere L.N., Kosovrasti K., Nalivaika E.A., Somasundaran M., Ali A., Mansky L.M., Kurt Yilmaz N., Schiffer C.A. Inhibiting HTLV-1 protease: a viable antiviral target. ACS Chem. Biol. 2021;16(3):529–538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8126997</ArticleId><ArticleId IdType="pubmed">33619959</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson N.M., Cucunuba Z.M., Dorigatti I., Nedjati-Gilani G.L., Donnelly C.A., Basanez M.G., Nouvellet P., Lessler J. EPIDEMIOLOGY. Countering the Zika epidemic in Latin America. Science. 2016;353(6297):353–354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5475255</ArticleId><ArticleId IdType="pubmed">27417493</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang H.H., Huber R.G., Bond P.J., Grad Y.H., Camerini D., Maurer-Stroh S., Lipsitch M. Systematic analysis of protein identity between Zika virus and other arthropod-borne viruses. Bull. World Health Organ. 2017;95(7):517–525I.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5487971</ArticleId><ArticleId IdType="pubmed">28670016</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell P.K. The Zika pandemic—a perfect storm? PLoS Negl. Trop. Dis. 2016;10(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4798639</ArticleId><ArticleId IdType="pubmed">26991663</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Valderramos S.G., Wu A., Ouyang S., Li C., Brasil P., Bonaldo M., Coates T., Nielsen-Saines K., Jiang T., Aliyari R., Cheng G. From mosquitos to humans: genetic evolution of Zika virus. Cell Host Microbe. 2016;19(5):561–565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5648540</ArticleId><ArticleId IdType="pubmed">27091703</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyle J.L., Harris E. Global spread and persistence of dengue. Annu. Rev. Microbiol. 2008;62:71–92.</Citation><ArticleIdList><ArticleId IdType="pubmed">18429680</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L., Drake J.M., Brownstein J.S., Hoen A.G., Sankoh O., Myers M.F., George D.B., Jaenisch T., Wint G.R., Simmons C.P., Scott T.W., Farrar J.J., Hay S.I. The global distribution and burden of dengue. Nature. 2013;496(7446):504–507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651993</ArticleId><ArticleId IdType="pubmed">23563266</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang C., Keller T.H., Luo D. Zika virus protease: an antiviral drug target. Trends Microbiol. 2017;25(10):797–808.</Citation><ArticleIdList><ArticleId IdType="pubmed">28789826</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble C.G., Seh C.C., Chao A.T., Shi P.Y. Ligand-bound structures of the dengue virus protease reveal the active conformation. J. Virol. 2012;86(1):438–446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3255909</ArticleId><ArticleId IdType="pubmed">22031935</ArticleId></ArticleIdList></Reference><Reference><Citation>Robin G., Chappell K., Stoermer M.J., Hu S.H., Young P.R., Fairlie D.P., Martin J.L. Structure of West Nile virus NS3 protease: ligand stabilization of the catalytic conformation. J. Mol. Biol. 2009;385(5):1568–1577.</Citation><ArticleIdList><ArticleId IdType="pubmed">19059417</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo D., Xu T., Hunke C., Gruber G., Vasudevan S.G., Lescar J. Crystal structure of the NS3 protease-helicase from dengue virus. J. Virol. 2008;82(1):173–183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2224403</ArticleId><ArticleId IdType="pubmed">17942558</ArticleId></ArticleIdList></Reference><Reference><Citation>Erbel P., Schiering N., D'Arcy A., Renatus M., Kroemer M., Lim S.P., Yin Z., Keller T.H., Vasudevan S.G., Hommel U. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat. Struct. Mol. Biol. 2006;13(4):372–373.</Citation><ArticleIdList><ArticleId IdType="pubmed">16532006</ArticleId></ArticleIdList></Reference><Reference><Citation>Phoo W.W., Li Y., Zhang Z., Lee M.Y., Loh Y.R., Tan Y.B., Ng E.Y., Lescar J., Kang C., Luo D. Structure of the NS2B-NS3 protease from Zika virus after self-cleavage. Nat. Commun. 2016;7:13410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5116066</ArticleId><ArticleId IdType="pubmed">27845325</ArticleId></ArticleIdList></Reference><Reference><Citation>Phoo W.W., Zhang Z., Wirawan M., Chew E.J.C., Chew A.B.L., Kouretova J., Steinmetzer T., Luo D. Structures of Zika virus NS2B-NS3 protease in complex with peptidomimetic inhibitors. Antiviral Res. 2018;160:17–24.</Citation><ArticleIdList><ArticleId IdType="pubmed">30315877</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsche C., Holloway S., Schirmeister T., Klein C.D. Biochemistry and medicinal chemistry of the dengue virus protease. Chem. Rev. 2014;114(22):11348–11381.</Citation><ArticleIdList><ArticleId IdType="pubmed">25268322</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Z., Patel S.J., Wang W.L., Chan W.L., Ranga Rao K.R., Wang G., Ngew X., Patel V., Beer D., Knox J.E., Ma N.L., Ehrhardt C., Lim S.P., Vasudevan S.G., Keller T.H. Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors. Bioorg. Med. Chem. Lett. 2006;16(1):40–43.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246563</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Z., Patel S.J., Wang W.L., Wang G., Chan W.L., Rao K.R., Alam J., Jeyaraj D.A., Ngew X., Patel V., Beer D., Lim S.P., Vasudevan S.G., Keller T.H. Peptide inhibitors of dengue virus NS3 protease. Part 1: warhead. Bioorg. Med. Chem. Lett. 2006;16(1):36–39.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246553</ArticleId></ArticleIdList></Reference><Reference><Citation>Poulsen A., Kang C., Keller T.H. Drug design for flavivirus proteases: what are we missing? Curr. Pharm. Des. 2014;20(21):3422–3427.</Citation><ArticleIdList><ArticleId IdType="pubmed">24001226</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsche C., Onagi H., Quek J.P., Otting G., Luo D., Huber T. Biocompatible macrocyclization between cysteine and 2-Cyanopyridine generates stable peptide inhibitors. Org. Lett. 2019;21(12):4709–4712.</Citation><ArticleIdList><ArticleId IdType="pubmed">31188009</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Zhang Z., Phoo W.W., Loh Y.R., Li R., Yang H.Y., Jansson A.E., Hill J., Keller T.H., Nacro K., Luo D., Kang C. Structural insights into the inhibition of Zika virus NS2B-NS3 protease by a small-molecule inhibitor. Structure. 2018;26(4):555–564. (e3)</Citation><ArticleIdList><ArticleId IdType="pubmed">29526431</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H., Ren J., Nocadello S., Rice A.J., Ojeda I., Light S., Minasov G., Vargas J., Nagarathnam D., Anderson W.F., Johnson M.E. Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus. Antiviral Res. 2017;139:49–58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5627664</ArticleId><ArticleId IdType="pubmed">28034741</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Li Y., Loh Y.R., Phoo W.W., Hung A.W., Kang C., Luo D. Crystal structure of unlinked NS2B-NS3 protease from Zika virus. Science. 2016;354(6319):1597–1600.</Citation><ArticleIdList><ArticleId IdType="pubmed">27940580</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan J.F., Chik K.K., Yuan S., Yip C.C., Zhu Z., Tee K.M., Tsang J.O., Chan C.C., Poon V.K., Lu G., Zhang A.J., Lai K.K., Chan K.H., Kao R.Y., Yuen K.Y. Novel antiviral activity and mechanism of bromocriptine as a Zika virus NS2B-NS3 protease inhibitor. Antiviral Res. 2017;141:29–37.</Citation><ArticleIdList><ArticleId IdType="pubmed">28185815</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss S., Nitsche C. Inhibitors of the Zika virus protease NS2B-NS3. Bioorg. Med. Chem. Lett. 2020;30(5):126965.</Citation><ArticleIdList><ArticleId IdType="pubmed">31980339</ArticleId></ArticleIdList></Reference><Reference><Citation>Behnam M.A., Nitsche C., Boldescu V., Klein C.D. The medicinal chemistry of dengue virus. J. Med. Chem. 2016;59(12):5622–5649.</Citation><ArticleIdList><ArticleId IdType="pubmed">26771861</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin K.H., Nalivaika E.A., Prachanronarong K.L., Yilmaz N.K., Schiffer C.A. Dengue protease substrate recognition: binding of the prime side. ACS Infect. Dis. 2016;2(10):734–743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5221572</ArticleId><ArticleId IdType="pubmed">27657335</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin K.H., Ali A., Rusere L., Soumana D.I., Kurt Yilmaz N., Schiffer C.A. Dengue Virus NS2B/NS3 protease inhibitors exploiting the prime Side. J. Virol. 2017:91(10).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5411607</ArticleId><ArticleId IdType="pubmed">28298600</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiryaev S.A., Farhy C., Pinto A., Huang C.T., Simonetti N., Elong Ngono A., Dewing A., Shresta S., Pinkerton A.B., Cieplak P., Strongin A.Y., Terskikh A.V. Characterization of the Zika virus two-component NS2B-NS3 protease and structure-assisted identification of allosteric small-molecule antagonists. Antiviral Res. 2017;143:218–229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5558795</ArticleId><ArticleId IdType="pubmed">28461069</ArticleId></ArticleIdList></Reference><Reference><Citation>Brecher M., Li Z., Liu B., Zhang J., Koetzner C.A., Alifarag A., Jones S.A., Lin Q., Kramer L.D., Li H. A conformational switch high-throughput screening assay and allosteric inhibition of the flavivirus NS2B-NS3 protease. PLoS Pathog. 2017;13(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5462475</ArticleId><ArticleId IdType="pubmed">28542603</ArticleId></ArticleIdList></Reference><Reference><Citation>Millies B., von Hammerstein F., Gellert A., Hammerschmidt S., Barthels F., Goppel U., Immerheiser M., Elgner F., Jung N., Basic M., Kersten C., Kiefer W., Bodem J., Hildt E., Windbergs M., Hellmich U.A., Schirmeister T. Proline-based allosteric inhibitors of Zika and dengue virus NS2B/NS3 proteases. J. Med. Chem. 2019;62(24):11359–11382.</Citation><ArticleIdList><ArticleId IdType="pubmed">31769670</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim L., Dang M., Roy A., Kang J., Song J. Curcumin allosterically inhibits the dengue NS2B-NS3 protease by disrupting its active conformation. ACS Omega. 2020;5(40):25677–25686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7557217</ArticleId><ArticleId IdType="pubmed">33073093</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsche C., Passioura T., Varava P., Mahawaththa M.C., Leuthold M.M., Klein C.D., Suga H., Otting G. De novo discovery of nonstandard macrocyclic peptides as noncompetitive inhibitors of the Zika virus NS2B-NS3 protease. ACS Med. Chem. Lett. 2019;10(2):168–174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6378662</ArticleId><ArticleId IdType="pubmed">30783498</ArticleId></ArticleIdList></Reference><Reference><Citation>Yildiz M., Ghosh S., Bell J.A., Sherman W., Hardy J.A. Allosteric inhibition of the NS2B-NS3 protease from dengue virus. ACS Chem. Biol. 2013;8(12):2744–2752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3923078</ArticleId><ArticleId IdType="pubmed">24164286</ArticleId></ArticleIdList></Reference><Reference><Citation>Raut R., Beesetti H., Tyagi P., Khanna I., Jain S.K., Jeankumar V.U., Yogeeswari P., Sriram D., Swaminathan S. A small molecule inhibitor of dengue virus type 2 protease inhibits the replication of all four dengue virus serotypes in cell culture. Virol. J. 2015;12:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4327787</ArticleId><ArticleId IdType="pubmed">25886260</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodenreider C., Beer D., Keller T.H., Sonntag S., Wen D., Yap L., Yau Y.H., Shochat S.G., Huang D., Zhou T., Caflisch A., Su X.C., Ozawa K., Otting G., Vasudevan S.G., Lescar J., Lim S.P. A fluorescence quenching assay to discriminate between specific and nonspecific inhibitors of dengue virus protease. Anal. Biochem. 2009;395(2):195–204.</Citation><ArticleIdList><ArticleId IdType="pubmed">19682971</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z., Brecher M., Deng Y.Q., Zhang J., Sakamuru S., Liu B., Huang R., Koetzner C.A., Allen C.A., Jones S.A., Chen H., Zhang N.N., Tian M., Gao F., Lin Q., Banavali N., Zhou J., Boles N., Xia M., Kramer L.D., Qin C.F., Li H. Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction. Cell Res. 2017;27(8):1046–1064.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5539352</ArticleId><ArticleId IdType="pubmed">28685770</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A., Liang B., Aarthy M., Singh S.K., Garg N., Mysorekar I.U., Giri R. Hydroxychloroquine inhibits Zika virus NS2B-NS3 protease. ACS Omega. 2018;3(12):18132–18141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6312647</ArticleId><ArticleId IdType="pubmed">30613818</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J., Thibaut H.J., Strating J.R.P.M., van Kuppeveld F.J.M. The life cycle of non-polio enteroviruses and how to target it. Nat. Rev. Microbiol. 2018;16(6):368–381.</Citation><ArticleIdList><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>Messacar K., Schreiner T.L., Maloney J.A., Wallace A., Ludke J., Oberste M.S., Nix W.A., Robinson C.C., Glode M.P., Abzug M.J., Dominguez S.R. A cluster of acute flaccid paralysis and cranial nerve dysfunction temporally associated with an outbreak of enterovirus D68 in children in Colorado, USA. Lancet. 2015;385(9978):1662–1671.</Citation><ArticleIdList><ArticleId IdType="pubmed">25638662</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm-Hansen C.C., Midgley S.E., Fischer T.K. Global emergence of enterovirus D68: a systematic review. Lancet Infect. Dis. 2016;16(5):e64–e75.</Citation><ArticleIdList><ArticleId IdType="pubmed">26929196</ArticleId></ArticleIdList></Reference><Reference><Citation>Winther B. In: Rhinoviruses, in International Encyclopedia of Public Health. Heggenhougen H.K., editor. Academic Press; Oxford: 2008. pp. 577–581.</Citation></Reference><Reference><Citation>Seipelt J., Guarne A., Bergmann E., James M., Sommergruber W., Fita I., Skern T. The structures of picornaviral proteinases. Virus Res. 1999;62(2):159–168.</Citation><ArticleIdList><ArticleId IdType="pubmed">10507325</ArticleId></ArticleIdList></Reference><Reference><Citation>Costenaro L., Kaczmarska Z., Arnan C., Janowski R., Coutard B., Sola M., Gorbalenya A.E., Norder H., Canard B., Coll M. Structural basis for antiviral inhibition of the main protease, 3C, from human enterovirus 93. J. Virol. 2011;85(20):10764–10773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3187475</ArticleId><ArticleId IdType="pubmed">21835784</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J., George S., Kusov Y., Perbandt M., Anemuller S., Mesters J.R., Norder H., Coutard B., Lacroix C., Leyssen P., Neyts J., Hilgenfeld R. 3C protease of enterovirus 68: structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses. J. Virol. 2013;87(8):4339–4351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624371</ArticleId><ArticleId IdType="pubmed">23388726</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai W., Jochmans D., Xie H., Yang H., Li J., Su H., Chang D., Wang J., Peng J., Zhu L., Nian Y., Hilgenfeld R., Jiang H., Chen K., Zhang L., Xu Y., Neyts J., Liu H. Design, synthesis, and biological evaluation of Peptidomimetic aldehydes as broad-Spectrum inhibitors against enterovirus and SARS-CoV-2. J. Med. Chem. 2021</Citation><ArticleIdList><ArticleId IdType="pubmed">33872498</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden F.G., Turner R.B., Gwaltney J.M., Chi-Burris K., Gersten M., Hsyu P., Patick A.K., Smith G.J., 3rd, Zalman L.S. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob. Agents Chemother. 2003;47(12):3907–3916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC296196</ArticleId><ArticleId IdType="pubmed">14638501</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick A.K., Brothers M.A., Maldonado F., Binford S., Maldonado O., Fuhrman S., Petersen A., Smith G.J., 3rd, Zalman L.S., Burns-Naas L.A., Tran J.Q. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother. 2005;49(6):2267–2275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1140523</ArticleId><ArticleId IdType="pubmed">15917520</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu G., Qi J., Chen Z., Xu X., Gao F., Lin D., Qian W., Liu H., Jiang H., Yan J., Gao G.F. Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J. Virol. 2011;85(19):10319–10331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196414</ArticleId><ArticleId IdType="pubmed">21795339</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Fan T., Yao X., Wu Z., Guo L., Lei X., Wang J., Wang M., Jin Q., Cui S. Crystal structures of enterovirus 71 3C protease complexed with rupintrivir reveal the roles of catalytically important residues. J. Virol. 2011;85(19):10021–10030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196404</ArticleId><ArticleId IdType="pubmed">21813612</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y., Wang Y., Cao L., Wang P., Qing J., Zheng Q., Shang L., Yin Z., Sun Y. A conserved inhibitory mechanism of a Lycorine derivative against enterovirus and hepatitis C virus. Antimicrob. Agents Chemother. 2016;60(2):913–924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4750679</ArticleId><ArticleId IdType="pubmed">26596952</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong E., Du H., Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 2020;20(5):533–534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159018</ArticleId><ArticleId IdType="pubmed">32087114</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Peng F., Wang R., Yange M., Guan K., Jiang T., Xu G., Sun J., Chang C. The deadly coronaviruses: the 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J. Autoimmun. 2020;109:102434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7126544</ArticleId><ArticleId IdType="pubmed">32143990</ArticleId></ArticleIdList></Reference><Reference><Citation>da Costa V.G., Moreli M.L., Saivish M.V. The emergence of SARS, MERS and novel SARS-2 coronaviruses in the 21st century. Arch. Virol. 2020;165(7):1517–1526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7176030</ArticleId><ArticleId IdType="pubmed">32322993</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Horby P.W., Hayden F.G., Gao G.F. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470–473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7135038</ArticleId><ArticleId IdType="pubmed">31986257</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziebuhr J. Molecular biology of severe acute respiratory syndrome coronavirus. Curr. Opin. Microbiol. 2004;7(4):412–419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108451</ArticleId><ArticleId IdType="pubmed">15358261</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceraolo C., Giorgi F.M. Genomic variance of the 2019-nCoV coronavirus. J. Med. Virol. 2020;92(5):522–528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166773</ArticleId><ArticleId IdType="pubmed">32027036</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullrich S., Nitsche C. The SARS-CoV-2 main protease as drug target. Bioorg. Med. Chem. Lett. 2020;30(17):127377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7331567</ArticleId><ArticleId IdType="pubmed">32738988</ArticleId></ArticleIdList></Reference><Reference><Citation>Grum-Tokars V., Ratia K., Begaye A., Baker S.C., Mesecar A.D. Evaluating the 3C-like protease activity of SARS-coronavirus: recommendations for standardized assays for drug discovery. Virus Res. 2008;133(1):63–73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4036818</ArticleId><ArticleId IdType="pubmed">17397958</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong N., Zhang S., Zou P., Chen J., Kang X., Li Z., Liang C., Jin C., Xia B. Without its N-finger, the main protease of severe acute respiratory syndrome coronavirus can form a novel dimer through its C-terminal domain. J. Virol. 2008;82(9):4227–4234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2293041</ArticleId><ArticleId IdType="pubmed">18305043</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia B., Kang X. Activation and maturation of SARS-CoV main protease. Protein Cell. 2011;2(4):282–290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4875205</ArticleId><ArticleId IdType="pubmed">21533772</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho B.L., Cheng S.C., Shi L., Wang T.Y., Ho K.I., Chou C.Y. Critical assessment of the important residues involved in the dimerization and catalysis of MERS coronavirus Main protease. PLoS One. 2015;10(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4682845</ArticleId><ArticleId IdType="pubmed">26658006</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillaiyar T., Manickam M., Namasivayam V., Hayashi Y., Jung S.H. An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy. J. Med. Chem. 2016;59(14):6595–6628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7075650</ArticleId><ArticleId IdType="pubmed">26878082</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wei P., Fan K., Liu Y., Lai L. 3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism. Biochemistry. 2004;43(15):4568–4574.</Citation><ArticleIdList><ArticleId IdType="pubmed">15078103</ArticleId></ArticleIdList></Reference><Reference><Citation>Muramatsu T., Takemoto C., Kim Y.T., Wang H., Nishii W., Terada T., Shirouzu M., Yokoyama S. SARS-CoV 3CL protease cleaves its C-terminal autoprocessing site by novel subsite cooperativity. Proc. Natl. Acad. Sci. U. S. A. 2016;113(46):12997–13002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5135343</ArticleId><ArticleId IdType="pubmed">27799534</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J., Worrall L.J., Vuckovic M., Rosell F.I., Gentile F., Ton A.T., Caveney N.A., Ban F., Cherkasov A., Paetzel M., Strynadka N.C.J. Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site. Nat. Commun. 2020;11(1):5877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7674412</ArticleId><ArticleId IdType="pubmed">33208735</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue X., Yu H., Yang H., Xue F., Wu Z., Shen W., Li J., Zhou Z., Ding Y., Zhao Q., Zhang X.C., Liao M., Bartlam M., Rao Z. Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design. J. Virol. 2008;82(5):2515–2527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2258912</ArticleId><ArticleId IdType="pubmed">18094151</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin S.A., Banerjee S., Ghosh K., Gayen S., Jha T. Protease targeted COVID-19 drug discovery and its challenges: insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors. Bioorg. Med. Chem. 2021;29:115860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7647411</ArticleId><ArticleId IdType="pubmed">33191083</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang R., Wang L., Zhang N., Deng X., Su M., Su Y., Hu L., He C., Ying T., Jiang S., Yu F. Development of small-molecule MERS-CoV inhibitors. Viruses. 2018;10(12):721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6316138</ArticleId><ArticleId IdType="pubmed">30562987</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman R.L., Kania R.S., Brothers M.A., Davies J.F., Ferre R.A., Gajiwala K.S., He M., Hogan R.J., Kozminski K., Li L.Y., Lockner J.W., Lou J., Marra M.T., Mitchell L.J., Jr., Murray B.W., Nieman J.A., Noell S., Planken S.P., Rowe T., Ryan K., Smith G.J., 3rd, Solowiej J.E., Steppan C.M., Taggart B. Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19. J. Med. Chem. 2020;63(21):12725–12747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7571312</ArticleId><ArticleId IdType="pubmed">33054210</ArticleId></ArticleIdList></Reference><Reference><Citation>Boras B., Jones R.M., Anson B.J., Arenson D., Aschenbrenner L., Bakowski M.A., Beutler N., Binder J., Chen E., Eng H., Hammond J., Hoffman R., Kadar E.P., Kania R., Kimoto E., Kirkpatrick M.G., Lanyon L., Lendy E.K., Lillis J.R., Luthra S.A., Ma C., Noell S., Obach R.S., O’Brien M.N., O’Connor R., Ogilvie K., Owen D., Pettersson M., Reese M.R., Rogers T., Rossulek M.I., Sathish J.G., Steppan C., Ticehurst M., Updyke L.W., Zhu Y., Wang J., Chatterjee A.K., Mesecar A.D., Anderson A.S., Allerton C. Discovery of a novel inhibitor of coronavirus 3CL protease as a clinical candidate for the potential treatment of COVID-19. BioRxiv. 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>